Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06791525
PHASE4

Tirbanibulin for Pediatric Warts

Sponsor: The Skin Center Dermatology Group

View on ClinicalTrials.gov

Summary

Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.

Official title: Single-arm, Open-label Study of Tirbanibulin 1% Ointment to Treat Warts on the Hands in Pediatric Patients

Key Details

Gender

All

Age Range

8 Years - 18 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-05-01

Completion Date

2025-12-30

Last Updated

2025-05-15

Healthy Volunteers

No

Conditions

Interventions

DRUG

Tirbanibulin ointment 1%

Topical application

Locations (1)

The Skin Center Dermatology Group

New City, New York, United States